5. References

  1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2023. Available at: http://clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/. Accessed May 31, 2023.
  2. IBM Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www-micromedexsolutions-com.libproxy.uthscsa.edu/ (cited: May 31, 2023).
  3. Memantine tablets/oral solution (Namenda®) package insert. Allegan USA, Inc., November 2018.
  4. Memantine extended-release capsules (Namenda XR®) package insert. Allergan USA, Inc., November 2019.
  5. Memantine and donepezil extended-release capsules (Namzaric®) package insert. Allergan USA, Inc., January 2019.
  6. Tariot PN, Farlow MR, Grossberg GT, et al, for the Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317-24.
  7. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366:893-903.
  8. Tricco AC, Ashoor HM, Soobiah C, et al. Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer’s disease: systematic review and network metaanalysis. J Am Geriatr Soc. 2018;66(1):170–8.
  9. Emre M, Tsolaki M, Bonuccelli U, et al.  Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:969–77.
  10. Leroi I, Overshott R, Byrne EJ, et al.  Randomized controlled trial of memantine in dementia associated with Parkinson's disease.  Mov Disord. 2009;24(8):1217-21.